Skip to content
Exclusive CEO Interviews
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

✨ Onyx Summary ImmunityBio reported early Phase I results from its QUILT-106 trial showing complete responses in the first two patients with relapsed Waldenström macroglobulinemia treated with its investigational CD19 CAR-NK therapy, given alone or with rituximab. Both heavily pretreated patients achieved remission without significant toxicities, and the therapy was delivered

Belite Bio Announces Registered Direct Offering of $15 Million

Belite Bio Announces Registered Direct Offering of $15 Million

✨ Onyx Summary Belite Bio entered a registered direct offering with a single large existing institutional shareholder to sell 230,770 ADSs and accompanying five-year warrants for another 230,770 ADSs at $65 per unit, for gross proceeds of about $15M (with up to an additional ~$15M possible upon warrant exercise)

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

✨ Onyx Summary Keros Therapeutics announced a strategic realignment to focus resources on its lead program, KER-065, and discontinue internal development of cibotercept following Phase 2 data in pulmonary arterial hypertension. The company also implemented board and leadership changes, including appointing Jean-Jacques Bienaimé as Chair and promoting Lorena Lerner, Ph.D.

Geron Appoints Harout Semerjian as President and Chief Executive Ocer

Geron Appoints Harout Semerjian as President and Chief Executive Ocer

✨ Onyx Summary Geron Corporation appointed Harout Semerjian as President and Chief Executive Officer, effective August 7, 2025, succeeding Interim CEO Dawn Carter Bir, who will remain on the Board of Directors. Semerjian, a 30-year hematology and oncology veteran with leadership roles at Novartis, Ipsen, and GlycoMimetics, joins Geron as it

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

✨ Onyx Summary The American Cancer Society announced a new partnership with Guardant Health to expand nationwide cancer screening initiatives, including public awareness campaigns, community-based interventions, and state-level coalition work to remove barriers to care. By combining ACS’s reach with Guardant’s innovation, the collaboration aims to close persistent screening

Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives

Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives

✨ Onyx Summary Affinia Therapeutics has partnered with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium to raise awareness of BAG3 dilated cardiomyopathy (DCM) and drive early genetic testing for this life-threatening heart disease. The collaboration underscores the growing role of precision medicine in cardiovascular care and highlights Affinia’s

Verily awarded research grant from The Michael J. Fox Foundation to generate one of the world’s largest, high-dimensional molecular datasets of Parkinson’s patients

Verily awarded research grant from The Michael J. Fox Foundation to generate one of the world’s largest, high-dimensional molecular datasets of Parkinson’s patients

✨ Onyx Summary Verily announced it has received a $14.7M grant from The Michael J. Fox Foundation to generate one of the most comprehensive molecular datasets for Parkinson’s disease, leveraging biospecimens and multimodal data from the Personalized Parkinson’s Project. By making this resource publicly available through its Workbench

Verily welcomes new organizations who will use Workbench to manage large biomedical datasets and accelerate research

Verily welcomes new organizations who will use Workbench to manage large biomedical datasets and accelerate research

✨ Onyx Summary Verily announced new institutions adopting its Workbench platform—including NashBio, the University of Oxford, and NIH’s CARD program—while rolling out enhanced tools for data governance, analysis, and discovery. As biomedical data grows exponentially, these expansions position Workbench as a key infrastructure for harnessing complex datasets, enabling

Mongoose Bio Recognized as Top-10 Most Promising Biotech Companies

Mongoose Bio Recognized as Top-10 Most Promising Biotech Companies

✨ Onyx Summary Mongoose Bio, a Houston-based clinical-stage biotech developing next-generation precision TCR-T therapies for solid tumors, was named one of the top 10 most promising companies at the 13th Annual Texas Life Science Forum. The recognition highlights growing investor and scientific confidence in Mongoose Bio’s pioneering T-cell platform, marking